We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Results from an independent retrospective evaluation of a novel treatment protocol
with Copaxone demonstrated long-term suppression of clinical and magnetic resonance
imaging (MRI) activity in patients with very aggressive relapsing-remitting
multiple sclerosis (RRMS).
Forest Laboratories has announced results of two analyses of several studies
demonstrating that Campral delayed-release tablets are safe and well-tolerated
in the long-term treatment of alcohol dependence.
GenVec has presented safety and immune response data from the first of several
ongoing Phase I clinical trials involving an HIV vaccine candidate developed
jointly by GenVec and the Vaccine Research Center (VRC) of the NIH's National
Institute of Allergy and Infectious Diseases.
Human Genome Sciences has announced the results of a Phase II clinical trial
of Albuferon in patients with chronic hepatitis C who are naive to interferon-alpha
treatments.
CollaGenex Pharmaceuticals has announced the results of a double-blinded, placebo-controlled
Phase II clinical study designed to evaluate the safety and efficacy of COL-3
for the treatment of rosacea.
The results of Schwarz Pharma's Phase III trials with fesoterodine for the treatment
of overactive bladder syndrome have demonstrated statistically significant improvements
in symptoms.
Acusphere has met with various representatives of the Division of Medical Imaging
and Radiopharmaceuticals at the FDA to discuss clinical trials progress and
a potential new drug application (NDA) for AI-700, leading to a revision of
the company's statistical analysis plan.
Genentech and Roche have announced that an interim analysis of a Phase III study
of Avastin plus paclitaxel chemotherapy in first-line metastatic breast cancer
met its primary efficacy endpoint of showing an improvement in progression-free
survival, compared to chemotherapy alone.
Neurocrine Biosciences has submitted a new drug application (NDA) to the FDA
for Indiplon capsules for the treatment of insomnia in both adult and elderly
patients.